Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning and deep learning-based drug-drug interactions prediction: a systematic review focused on anticancer drugs.

NPJ precision oncology·2026
Same author

Digital Microsteps as Scalable Adjuncts for Adults Using GLP-1 Receptor Agonists: A Randomized Clinical Trial.

JAMA network open·2026
Same author

Unseen Insights: An AI-Powered Exploration of Secure Patient Messages in Ophthalmology.

medRxiv : the preprint server for health sciences·2026
Same author

Effect of race and sex on lupus diagnosis in primary care: A randomized factorial survey study.

PloS one·2026
Same author

Key takeaways from Stanford's symposium on AI for Data Science.

Journal of clinical and translational science·2025
Same author

Optimizing large language models for detecting symptoms of depression/anxiety in chronic diseases patient communications.

NPJ digital medicine·2025
Same journal

Closing Diabetes Disparities-Is Technology Access Enough?

JAMA network open·2026
Same journal

Clinician Use of Home-Based Medical Care for Medicaid Beneficiaries.

JAMA network open·2026
Same journal

Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial.

JAMA network open·2026
Same journal

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma.

JAMA network open·2026
Same journal

Breast Cancer Survival in Asian American Patients.

JAMA network open·2026
Same journal

Social Determinants of Health and Continuous Glucose Monitoring Metrics in Type 1 or Type 2 Diabetes.

JAMA network open·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

Patient Experiences With GLP-1 Receptor Agonists.

Isabella de Vere Hunt1,2, Mariana Ramirez-Posada2,3, Christopher Sam Babu4

  • 1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

JAMA Network Open
|June 5, 2026
PubMed
Summary
This summary is machine-generated.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) aid weight loss but require lifestyle changes for sustained benefits. Patient experiences highlight variable support and access challenges, emphasizing the need for integrated care strategies.

More Related Videos

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
09:16

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

Related Experiment Videos

Last Updated: Jun 6, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
09:16

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

Area of Science:

  • Pharmacology and Endocrinology
  • Behavioral Medicine
  • Qualitative Health Research

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective obesity treatments, but high discontinuation rates and weight regain post-treatment are significant challenges.
  • Limited research explores patient experiences with GLP-1 RAs outside of type 2 diabetes management, hindering understanding of long-term adherence and effectiveness.

Purpose of the Study:

  • To investigate the lived experiences of patients using GLP-1 RAs for weight management.
  • To identify factors influencing treatment adherence and long-term success.
  • To inform the development of optimal strategies for sustained weight management.

Main Methods:

  • Qualitative study employing inductive thematic analysis of semistructured video interviews.
  • 30 adult participants from 15 US states, including current and former GLP-1 RA users for various indications.
  • Recruitment via ResearchMatch and snowball sampling.

Main Results:

  • Eight key themes emerged, categorized into patient-reported benefits/trade-offs and socio-clinical context.
  • Benefits included reduced appetite ('food noise'); however, GLP-1 RAs were not seen as a standalone solution.
  • Adverse effects, stigma, variable clinical support, cost, and access were significant challenges, though shared experiences were valued.

Conclusions:

  • GLP-1 RA therapy facilitates, rather than replaces, lifestyle changes for weight management.
  • Behavioral interventions are crucial for sustaining treatment benefits.
  • Standardized patient education and clinical support guidelines are needed to manage expectations and improve long-term outcomes.